Pfizer's experimental treatment for a type of bladder cancer significantly improved the time that patients remained free of ...

From the death of folk music star Peter Yarrow of Peter, Paul and Mary to good news from broadcasting legend Dick Vitale, ...

If approved, Pfizer’s sasanlimab will distinguish itself from Merck’s blockbuster Keytruda as the first PD-1 inhibitor ...

Pfizer’s “golden egg” has hatched. The subcutaneous PD-1 inhibitor improved outcomes when added to the standard of care in ...

Pfizer's Phase 3 CREST trial results highlight the efficacy of sasanlimab combined with BCG in treating high-risk non-muscle invasive bladder cancer.

Pfizer on Friday said the pivotal Phase 3 study evaluating sasanlimab in combination with standard-of-care Bacillus Calmette-Guerin, or BCG, as induction therapy with or without maintenance in ...

Cancer diagnostics company Pacific Edge's shares are in a trading halt while it considers the implications of new information ...

Pfizer (PFE) announced positive topline results from its pivotal Phase 3 CREST trial evaluating sasanlimab, an investigational anti-PD-1 ...

Prostate cancer is usually treated with surgery and radiation therapy, but these can have drastic side effects. A new ...

NZX-listed cancer diagnostics company Pacific Edge will need to “batten down the hatches” following a long-awaited decision ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

About 70 per cent of people over the age of 70 have nocturia - the need to go to the toilet in the middle of the night. But ...